(Reuters) – Modern Inc. has begun dosing patients in a mid- or late-stage stage of its COVID-19 vaccine, mRNA-1273, into children six months to under 12, the company said Tuesday.
The study will evaluate the safety and efficacy of two doses of mRNA-1273 distributed 28 days apart and intends to enroll about 6,750 children in the United States and Canada.
The vaccine is already authorized for emergency use in Americans over 18 years of age.
In a separate study that began in December, Moderna is also testing mRNA-1273 in adolescents between the ages of 12 and 18.
The latest study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Authority for Advanced Research and Development (BARDA).
Reports from Manojna Maddipatla to Bengaluru; Edited by Shailesh Kuber